{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:34:26Z","timestamp":1791581666299,"version":"4.3.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Youth Project of Hainan Natural Science Foundation","award":["822QN459"],"award-info":[{"award-number":["822QN459"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82371268"],"award-info":[{"award-number":["82371268"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"DOI":"10.1186\/s12883-025-04428-6","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T11:53:09Z","timestamp":1762775589000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The role of gut microbiota tyrosine decarboxylases in levodopa pharmacokinetics: insights from a levodopa challenge test"],"prefix":"10.1186","volume":"25","author":[{"given":"Yukun","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronggui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangxin","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiguo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"issue":"5","key":"4428_CR1","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S1474-4422(21)00030-2","volume":"20","author":"E Tolosa","year":"2021","unstructured":"Tolosa E, Garrido A, Scholz SW, Poewe W. Challenges in the diagnosis of parkinson\u2019s disease. LANCET NEUROL. 2021;20(5):385\u201397.","journal-title":"LANCET NEUROL"},{"issue":"8","key":"4428_CR2","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.2174\/1570159X15666170510143821","volume":"16","author":"N Tambasco","year":"2018","unstructured":"Tambasco N, Romoli M, Calabresi P. Levodopa in parkinson\u2019s disease: current status and future developments. CURR NEUROPHARMACOL. 2018;16(8):1239\u201352.","journal-title":"CURR NEUROPHARMACOL"},{"issue":"6","key":"4428_CR3","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1001\/jama.2019.22360","volume":"323","author":"MJ Armstrong","year":"2020","unstructured":"Armstrong MJ, Okun MS. Diagnosis and treatment of Parkinson disease: A review. JAMA-J AM MED ASSOC. 2020;323(6):548\u201360.","journal-title":"JAMA-J AM MED ASSOC"},{"issue":"6","key":"4428_CR4","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s00702-025-02893-4","volume":"132","author":"P Riederer","year":"2025","unstructured":"Riederer P, Strobel S, Nagatsu T, Watanabe H, Chen X, Loschmann PA, Sian-Hulsmann J, Jost WH, Muller T, Dijkstra JM, et al. Levodopa treatment: impacts and mechanisms throughout parkinson\u2019s disease progression. J NEURAL TRANSM. 2025;132(6):743\u201379.","journal-title":"J NEURAL TRANSM"},{"key":"4428_CR5","doi-asserted-by":"publisher","first-page":"1046910","DOI":"10.3389\/fneur.2023.1046910","volume":"14","author":"Z Zhong","year":"2023","unstructured":"Zhong Z, Ye M, Yan F. A review of studies on gut microbiota and Levodopa metabolism. FRONT NEUROL. 2023;14:1046910.","journal-title":"FRONT NEUROL"},{"issue":"7","key":"4428_CR6","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.2174\/1570159X21666221019115716","volume":"21","author":"K Xu","year":"2023","unstructured":"Xu K, Sheng S, Zhang F. Relationship between gut bacteria and Levodopa metabolism. CURR NEUROPHARMACOL. 2023;21(7):1536\u201347.","journal-title":"CURR NEUROPHARMACOL"},{"key":"4428_CR7","doi-asserted-by":"crossref","unstructured":"Maini RV, Bess EN, Bisanz JE, Turnbaugh PJ, Balskus EP. Discovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism. Science. 2019;364(6445):eaau6323.","DOI":"10.1126\/science.aau6323"},{"issue":"1","key":"4428_CR8","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/s41467-019-08294-y","volume":"10","author":"SP van Kessel","year":"2019","unstructured":"van Kessel SP, Frye AK, El-Gendy AO, Castejon M, Keshavarzian A, van Dijk G, El AS. Gut bacterial tyrosine decarboxylases restrict levels of Levodopa in the treatment of parkinson\u2019s disease. NAT COMMUN. 2019;10(1):310.","journal-title":"NAT COMMUN"},{"issue":"22","key":"4428_CR9","doi-asserted-by":"publisher","first-page":"e2443","DOI":"10.1212\/WNL.0000000000201204","volume":"99","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, He X, Mo C, Liu X, Li J, Yan Z, Qian Y, Lai Y, Xu S, Yang X, et al. Association between microbial tyrosine decarboxylase gene and Levodopa responsiveness in patients with Parkinson disease. NEUROLOGY. 2022;99(22):e2443\u201353.","journal-title":"NEUROLOGY"},{"issue":"1","key":"4428_CR10","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41531-021-00260-0","volume":"7","author":"SP van Kessel","year":"2021","unstructured":"van Kessel SP, Auvinen P, Scheperjans F, El AS. Gut bacterial tyrosine decarboxylase associates with clinical variables in a longitudinal cohort study of parkinsons disease. NPJ PARKINSONS DIS. 2021;7(1):115.","journal-title":"NPJ PARKINSONS DIS"},{"issue":"5","key":"4428_CR11","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1002\/mds.25383","volume":"28","author":"GT Stebbins","year":"2013","unstructured":"Stebbins GT, Goetz CG, Burn DJ, Jankovic J, Khoo TK, Tilley BC. How to identify tremor dominant and postural instability\/gait difficulty groups with the movement disorder society unified parkinson\u2019s disease rating scale: comparison with the unified parkinson\u2019s disease rating scale. Mov DISORD. 2013;28(5):668\u201370.","journal-title":"Mov DISORD"},{"issue":"15","key":"4428_CR12","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1002\/mds.23429","volume":"25","author":"CL Tomlinson","year":"2010","unstructured":"Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of Levodopa dose equivalency reporting in parkinson\u2019s disease. Mov DISORD. 2010;25(15):2649\u201353.","journal-title":"Mov DISORD"},{"issue":"9","key":"4428_CR13","doi-asserted-by":"publisher","first-page":"3135","DOI":"10.1007\/s00415-020-09810-7","volume":"268","author":"G Saranza","year":"2021","unstructured":"Saranza G, Lang AE. Levodopa challenge test: indications, protocol, and guide. J NEUROL. 2021;268(9):3135\u201343.","journal-title":"J NEUROL"},{"issue":"3","key":"4428_CR14","doi-asserted-by":"publisher","first-page":"234","DOI":"10.2174\/157488407781668802","volume":"2","author":"SP Khor","year":"2007","unstructured":"Khor SP, Hsu A. The pharmacokinetics and pharmacodynamics of Levodopa in the treatment of parkinson\u2019s disease. CURR CLIN PHARMACOL. 2007;2(3):234\u201343.","journal-title":"CURR CLIN PHARMACOL"},{"issue":"6","key":"4428_CR15","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1002\/ana.10189","volume":"51","author":"JG Nutt","year":"2002","unstructured":"Nutt JG, Carter JH, Lea ES, Sexton GJ. Evolution of the response to Levodopa during the first 4 years of therapy. ANN NEUROL. 2002;51(6):686\u201393.","journal-title":"ANN NEUROL"},{"issue":"3","key":"4428_CR16","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1111\/1462-2920.14919","volume":"22","author":"H Brussow","year":"2020","unstructured":"Brussow H. Parkinson disease, Levodopa and the gut microbiota-when microbiology Meets Pharmacology. ENVIRON MICROBIOL. 2020;22(3):808\u201312.","journal-title":"ENVIRON MICROBIOL"},{"issue":"3","key":"4428_CR17","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1002\/mdc3.13417","volume":"9","author":"Y Yamanishi","year":"2022","unstructured":"Yamanishi Y, Choudhury ME, Yoshida A, Hosokawa Y, Miyaue N, Tada S, Ando R, Murakami S, Miyamoto H, Nagai M. Impact of intestinal bacteria on Levodopa pharmacokinetics in LCIG therapy. MOV DISORD CLIN PRAC. 2022;9(3):362\u20138.","journal-title":"MOV DISORD CLIN PRAC"},{"issue":"5","key":"4428_CR18","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1111\/ene.15734","volume":"30","author":"V Leta","year":"2023","unstructured":"Leta V, Klingelhoefer L, Longardner K, Campagnolo M, Levent HC, Aureli F, Metta V, Bhidayasiri R, Chung-Faye G, Falup-Pecurariu C, et al. Gastrointestinal barriers to Levodopa transport and absorption in parkinson\u2019s disease. EUR J NEUROL. 2023;30(5):1465\u201380.","journal-title":"EUR J NEUROL"},{"issue":"1","key":"4428_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12979-023-00404-1","volume":"21","author":"BR Wei","year":"2024","unstructured":"Wei BR, Zhao YJ, Cheng YF, Huang C, Zhang F. Helicobacter pylori infection and parkinson\u2019s disease: etiology, pathogenesis and Levodopa bioavailability. IMMUN AGEING. 2024;21(1):1.","journal-title":"IMMUN AGEING"},{"issue":"1","key":"4428_CR20","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41531-022-00321-y","volume":"8","author":"M Beckers","year":"2022","unstructured":"Beckers M, Bloem BR, Verbeek MM. Mechanisms of peripheral Levodopa resistance in parkinson\u2019s disease. NPJ PARKINSONS DIS. 2022;8(1):56.","journal-title":"NPJ PARKINSONS DIS"},{"key":"4428_CR21","doi-asserted-by":"crossref","unstructured":"Danau A, Dumitrescu L, Lefter A, Tulba D, Popescu BO. Small Intestinal Bacterial Overgrowth as Potential Therapeutic Target in Parkinson\u2019s Disease. Int J Mol Sci. 2021;22(21):11663.","DOI":"10.3390\/ijms222111663"},{"issue":"9","key":"4428_CR22","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1002\/mds.25522","volume":"28","author":"A Fasano","year":"2013","unstructured":"Fasano A, Bove F, Gabrielli M, Petracca M, Zocco MA, Ragazzoni E, Barbaro F, Piano C, Fortuna S, Tortora A, et al. The role of small intestinal bacterial overgrowth in parkinson\u2019s disease. Mov DISORD. 2013;28(9):1241\u20139.","journal-title":"Mov DISORD"},{"issue":"7","key":"4428_CR23","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1002\/jcph.1096","volume":"58","author":"TF Sampaio","year":"2018","unstructured":"Sampaio TF, Dos SE, de Lima G, Dos AR, Da SR, Asano A, Asano N, Crovella S, de Souza P. MAO-B and COMT genetic variations associated with Levodopa treatment response in patients with parkinson\u2019s disease. J CLIN PHARMACOL. 2018;58(7):920\u20136.","journal-title":"J CLIN PHARMACOL"},{"issue":"2","key":"4428_CR24","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.parkreldis.2013.10.017","volume":"20","author":"D Devos","year":"2014","unstructured":"Devos D, Lejeune S, Cormier-Dequaire F, Tahiri K, Charbonnier-Beaupel F, Rouaix N, Duhamel A, Sablonniere B, Bonnet AM, Bonnet C, et al. Dopa-decarboxylase gene polymorphisms affect the motor response to L-dopa in parkinson\u2019s disease. PARKINSONISM RELAT D. 2014;20(2):170\u20135.","journal-title":"PARKINSONISM RELAT D"},{"issue":"Pt 5","key":"4428_CR25","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1093\/brain\/awv063","volume":"138","author":"C Moreau","year":"2015","unstructured":"Moreau C, Meguig S, Corvol JC, Labreuche J, Vasseur F, Duhamel A, Delval A, Bardyn T, Devedjian JC, Rouaix N, et al. Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in parkinson\u2019s disease. Brain. 2015;138(Pt 5):1271\u201383.","journal-title":"Brain"},{"issue":"2","key":"4428_CR26","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/jphp.13031","volume":"71","author":"SE Dos","year":"2019","unstructured":"Dos SE, Sampaio TF, Tenorio DSA, Bezerra LF, Da SR, Crovella S, Asano A, Asano N, de Souza P. The influence of SLC6A3 and DRD2 polymorphisms on levodopa-therapy in patients with sporadic parkinson\u2019s disease. J PHARM PHARMACOL. 2019;71(2):206\u201312.","journal-title":"J PHARM PHARMACOL"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-025-04428-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-025-04428-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-025-04428-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:03:13Z","timestamp":1762819393000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-025-04428-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4428"],"URL":"https:\/\/doi.org\/10.1186\/s12883-025-04428-6","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,10]]},"assertion":[{"value":"22 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Research Ethics Committee of the Affiliated Brain Hospital of Nanjing Medical University, Nanjing, China (No. 2020-KYl91-0\u00a0L). The study was registered in Chinese Clinical Trial Registration (No. ChiCTR2000039201, 2020-10-21). It complies with the Declaraiton of Helsinki. All participants were informed of the purpose of this study and provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"460"}}